Management of symptomatic uncomplicated diverticular disease (SUDD) of the colon with Clostridium butyricum CBM588 versus rifaximin: a retrospective cross-sectional study
In this retrospective comparison, Clostridium butyricum CBM588<sup>®</sup> demonstrated similar efficacy to rifaximin in preventing diverticulitis, with a potential advantage in subjective symptom improvement. These findings support further prospective studies to explore the role of CBM588<sup>®</sup> in SUDD management. Trial registration Clinicaltrial.gov reference: NCT06852274.
Authors
- L. Pallotta
- Maria Giovanna Graziani (ORCID: https://orcid.org/0000-0002-5417-6525)
- R. Urgesi (ORCID: https://orcid.org/0000-0002-8463-7310)
- Gianfranco Fanello
- Cristiano Pagnini (ORCID: https://orcid.org/0000-0001-9985-7490)
- Davide Sisti (ORCID: https://orcid.org/0000-0002-7925-7495)
- G. Villotti
- Amjad Khan (ORCID: https://orcid.org/0000-0002-2566-0393)
- Fernando De Angelis
- Francesco Di Pierro (ORCID: https://orcid.org/0000-0001-6654-8675)
- Nicola Zerbinati (ORCID: https://orcid.org/0000-0003-2177-9677)
- Maria Carla Di Paolo (ORCID: https://orcid.org/0000-0001-6891-4114)
- Alexander Bertuccioli (ORCID: https://orcid.org/0000-0002-3922-9115)
- Pavlos Antypas
Institutions
- University of Insubria (IT)
- Liaquat University of Medical & Health Sciences (PK)
- University of Urbino (IT)
- Azienda Ospedaliera San Giovanni Addolorata (IT)
- Velleja Research (IT)
- Sapienza University of Rome (IT)
Publication Details
- Journal
- International Journal of Colorectal Disease
- Published
- 2025-10-18
- DOI
- https://doi.org/10.1007/s00384-025-05005-6
- Primary Topic
- Diverticular Disease and Complications
- Type
- article
- Field-Weighted Citation Impact
- 0.00